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ABSTRAK
Akut myeloid leukemia (AML) adalah sub-jenis akut leukemia yang kebiasaannya 
mempunyai prognosis yang tidak baik. Protein Msi2 merupakan penanda prognostik 
yang baru yang telah dianggap sebagai sasaran baru untuk terapi AML. Setakat ini, 
kajian ekpresi Msi2 protein di dalam kes AML belum pernah dijalankan lagi. Tujuan 
utama kajian ini adalah untuk melihat ekspresi Msi2 protein pada pesakit AML 
menggunakan teknik immunohistokimia (IHC) dan mengaitkan ekspresi tersebut 
dengan prognostik yang telah dikenalpasti dan parameter klinikal dalam AML 
beserta survival keseluruhan (OS). Enam puluh empat biopsi trephine tulang sum-
sum telah melalui proses immunopewarnaan untuk Msi2 protein. Peratusan sel 
blast dengan reaksi positif dan intensiti pewarnaan cytoplasmic dan nuklear telah 
dinilai. Ekspresi Msi2 protein ditemui di dalam sejumlah 95.3% kes dengan corak 
Msi2 yang berbeza-beza antara kes. Dalam 71.9% kes, sel blast menunjukkan 
positivity selular secara keseluruhan dan 23.4% kes hanya menunjukkan positivity 
sitoplasma. Majoriti menunjukkan ekspresi Msi2 yang tinggi untuk pewarnaan 
cytoplasmic. Amat menariknya apabila terdapat korelasi yang signifikan antara 
jumlah pewarnaan selular total dan subkumpulan sitogenetik pertengahan (P = 
0.04). Hasil kajian menunjukkan bahawa majoriti daripada pesakit mempunyai 
ekspresi Msi2 yang tinggi tetapi ia tidak menunjukkan korelasi dengan OS. 
Walau bagaimanapun, ekspresi Msi2 telah menunjukkan korelasi yang baik 
dengan penemuan sitogenetik. Keputusan ini menunjukkan penyelidikan secara 
meluas pada masa hadapan perlu dijalankan untuk menentukan dengan lebih 
tepat peranan sel-sel blast yang positif Msi2 dalam AML di kalangan populasi di 
Malaysia dan juga menentukan korelasinya terhadap prognosis and keseluruhan 
kesejahteraan pesakit.
Kata kunci: AML, sitogenetik, immunohistokimia, Msi2 protein
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patients (Kumar 2011). Cytogenetic 
abnormalities can be found in up to 
60% of newly diagnosed AML cases 
(Kumar 2011). These cytogenetic 
aberrations permit patients’ risk to be 
categorised as favorable, intermediate, 
and adverse risk groups (Estey & 
Döhner 2006) depending on the 
presence or absence of specific 
chromosomal abnormalities (Kumar 
2011). Patients with t(8;21), t(15;17), and 
inv(16) were allocated to the “favorable 
risk” group; patients lacking any of 
these abnormalities and established to 
have abn(3q), del(5q), -5/-7, or complex 
karyotype were assigned to the “adverse 
risk” group; and patients with normal 
ABSTRACT 
Acute myeloid leukaemia (AML) is the most common subtype of acute leukaemias 
with a poor outcome. Msi2 protein is a newly discovered prognostic marker and 
it has been considered as a new target for therapy in AML. The study of Msi2 
protein expression in AML cases has not been performed in Malaysia, to date. 
The main aim of the present study was to observe the expression of Msi2 protein 
in AML patients by immunohistochemistry (IHC) and to correlate its expression 
with the well-established prognostic and clinical parameters in AML as well as 
the overall survival (OS). Sixty four bone marrow trephine biopsy sections were 
immunostained for Msi2 protein. The percentage of blasts with positive reaction 
and the intensity of the cytoplasmic and nuclear staining were evaluated. The 
expression of Msi2 protein was found in 95.3% cases with Msi2 pattern varying 
between the cases. In 71.9% of cases, the blasts showed total cellular positivity and 
23.4% cases showed only cytoplasmic positivity. Majority showed high expression 
of Msi2 for cytoplasmic staining. Interestingly, there was significant correlation 
between total cellular staining and the intermediate cytogenetic subgroup (P= 
0.04).  In conclusion, the results showed that the majority of the patients had high 
expression of Msi2 but this did not correlate to OS. However, the Msi2 expression 
correlated to the cytogenetic findings. The results suggest future extensive research 
to be conducted in order to ascertain the exact role of Msi2 positive blast cells in 
AML in our population and their association with prognosis and outcome. 
Keywords: AML, cytogenetics, immunohistochemistry, Msi2 protein
INTRODUCTION
Acute myeloid leukaemia (AML) is 
a group of clonal haematopoietic 
stem cell disorders, where failure to 
differentiate into mature cells and 
excessive proliferation in the bone 
marrow stem cells compartment, result 
in the accumulation of myeloblasts 
(Stone et al. 2004). In Malaysia, 
leukaemia is the seventh most common 
cancer, with an incidence of 2.9 per 
100,000 population accounting for all 
leukaemias (Meng et al. 2013). 
 It should be noted that cytogenetics 
is the most powerful prognostic factor 
for predicting remission rate, relapse 
and overall survival (OS) in AML 
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karyotype and numerical or other 
structural abnormalities, comprised the 
"intermediate risk" group (Grimwade 
et al. 2010). Cytogenetically normal 
AML (CN-AML) patients constitute the 
largest (approximately 45%) group of all 
patients (Foran 2010). Rearrangements 
and mutations of several genes such 
as Fms-like tyrosine kinase 3 (FLT3), 
nucleophosmin 1 (NPM1), and CCAAT 
enhancer-binding protein-αα(CEBPA) 
were identified in this group of patients 
and shown to be important prognostic 
factors (Swerdlow et al. 2008, Foran 
2010).
 The Musashi (Msi) gene family 
members, Msi1 and Msi2, are located 
on chromosome 12 and 17, respectively 
(Byers et al. 2011). They encoded for 
a group of RNA-binding proteins that 
bind, via 2 ribonucleoprotein-type RNA 
recognition motifs in their N-terminal, 
to consensus motifs in mRNAs to 
inhibit translation (Sakakibara et al. 
2002; Barbouti et al. 2003; Kawahara 
et al. 2008). In haematopoietic stem 
cells (HSCs), Msi2 is the predominant 
form expressed and its knockdown 
leads to reduced engraftment and 
depletion of HSCs in vivo (Kharas 
et al. 2010). Also, its expression is 
associated with up-regulation of cell 
cycle genes (RAS, mitogen-activated 
protein kinase, cyclin D1, and MYC) 
and with homeobox genes, including 
MEISI, HOXA9, and HOXA1 (Byers et 
al. 2011). Recently, Park et al. (2015) 
demonstrated that Msi2 directly 
maintains the mixed-lineage leukemia 
(MLL) self-renewal program by 
interacting with and retaining efficient 
translation of HOXA9, MYC, and IKZF2 
mRNAs.  Furthermore, Msi2 is highly 
expressed in human myeloid leukemia 
cell lines in which its depletion via 
inhibiton of Ki-67 expression leads to 
decreased proliferation and increased 
apoptosis (Kharas et al. 2010; Park et 
al. 2015; Han et al. 2015).
 Kharas et al. (2010) studied Msi2 
expression data gained from 436 AML 
patients. The expression of Msi2 was 
significantly associated with specific 
cytogenetic and molecular genetic 
aberrations. Patients with inversion of 
chromosome 16 showed lower Msi2 
levels comparative to other leukaemia 
subgroups, whereas Msi2 expression 
was higher in subjects harboring 
monosomy 7. Likewise, high Msi2 
expression was associated with FLT3 
internal tandem duplications and 
NPM1 mutations but not with mixed-
lineage-leukemia 1 partial tandem 
duplication (MLL-PTD) and CEBPA 
(Kharas et al. 2010).  
 Byers et al. (2011) measured Msi2 
protein level by immunohistochemistry 
(IHC) in 120 AML patients. Their study 
concluded that Msi2 is highly expressed 
in myeloblasts which associated with 
decreased survival in AML, suggesting 
its use as a new prognostic marker 
(Byers et al. 2011). 
 The objective of the study was to 
measure the expression of Msi2 protein 
in AML patients by IHC technique 
and to demonstrate the correlation 
between the Msi2 protein with several 
known prognostic parameters such as 
age of patients, white blood cell (WBC) 
count at diagnosis, French-American-
British (FAB) subtypes, cytogenetic 
categories as well as the remission 
status post induction and finally 
to correlate the expression of Msi2 
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with OS. Few previous studies have 
suggested that Msi2 protein is a useful 
new prognostic biomarker where high 
expression of this protein is associated 
with decreased survival in patients with 
AML. The knowledge gained not only 
to evaluate the effect of this protein in 
our local AML population, but it is also 
hoped to contribute to the strategies 
for the treatment of AML in order to 
improve our patients’ survival rate.
MATERIALS AND METHODS
SAMPLE SELECTION 
All the available cases with histological 
diagnosis of AML in Universiti 
Kebangsaan Malaysia Medical Centre 
(UKMMC) for 6 yrs were selected by 
using universal sampling. A total of 64 
cases of newly diagnosed AML were 
collected. Bone marrow (BM) trephine 
sections with at least 20% leukaemic 
blasts were selected as a part of the 
inclusion criteria to maintain adequacy 
of the specimen for evaluation. 
Meanwhile, all the hematoxylin and 
eosin (H&E) slides of BM trephine 
biopsy were reviewed and the paraffin 
embedded tissues were retrieved for 
whole tissue section and IHC for Msi2 
expression.
IMMUNOHISTOCHEMISTRY
Primary antibody rabbit monoclonal 
[EP1305Y] antibody specific to Msi2 
(Code No: ab76148, Abcam England) 
was diluted to optimal dilution 1:2000 
using Dako Antibody Diluent (Code 
No. S080983, Dako Denmark). The 
whole BM trephine biopsy sections 
were cut onto SuperfrostTM Plus 
coated slides (Thermo ScientificTM, 
USA). Furthermore, the staining was 
performed using the protocols from 
staining kit Dako REALTMEnvisionTM 
Detection System, Peroxidase/DAB+, 
Rabbit/Mouse (Code No. K5007, Dako 
Denmark). Washing steps between 
each reagent were performed using 
Lab Vision™ Tris-Buffered Saline and 
Tween™ 20 (20x) (Thermo Scientific™ 
USA). The DAB Substrate Working 
Solution was prepared by diluting 
the 50x concentrated Dako REALTM 
DAB+ chromogen with Dako REALTM 
Substrate Buffer (Code No. K5007, 
Dako Denmark). 
 The tissue sections were initially 
incubated on a slide warmer at 65ºC 
for 30 mins. Next, tissue sections 
were dewaxed using 2-steps Xylene 
(Merck Germany) and rehydrated 
using decreasing alcohol solutions 
(100%, 80% and 70%) prepared from 
100% Surgipath Reagent Alcohol 
(Leica Microsystems USA). Tissue 
sections were subsequently incubated 
with peroxidase blocking reagent 
H2O2 for 6 mins. Furthermore, tissue 
sections were pretreated using heat-
induced antigen retrieval Citrate 
Buffer Solution, pH 6.1 (DAKO) in the 
Pascal Pressurized Chamber (Dako 
Cytomation, USA) at 96°C for 40 
mins. Next, tissue sections were left 
to cool down at room temperature for 
20 mins. Slides were then incubated 
with primary antibody for 60 mins 
at room temperature, followed by 
secondary antibody incubation with 
Dako REALTM EnvisionTM/HRP, Rabbit/
Mouse (ENV) (Code No. K5007, 
Dako Denmark) for 30 mins. Tissue 
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sections were then incubated with 
DAB Substrate Working Solution for 7 
mins. After the procedures have been 
completed, slides were counterstained 
with Hematoxylin 2 (REF 7231, Thermo 
Scientific USA) for 5 seconds followed 
by dehydration step with increasing 
alcohol solutions (80%, 90% and 
100%) and 2-steps Xylene. Finally, the 
slides were mounted and cover slipped 
using DPX mounting medium (Cat. No.: 
100579, Merck Milipore Germany). 
 Normal placental tissue was used as 
a positive control and included with 
each batch of sections to confirm the 
consistency of the analyses.  It showed 
strong staining in trophoblast cells 
(Figure 1).
ANALYSIS OF IMMUNOSTAINED 
SLIDES FOR MSI2 EXPRESSION
The whole BM trephine biopsy sections 
immunostained for Msi2 were reviewed 
by two independent pathologists and 
scored qualitatively and quantitatively 
at x4 and x40 magnification. The 
discrepancies between the reviewers 
were resolved by consensus.
PERCENTAGE OF POSITIVE BLAST CELLS 
Msi2 expression was detected in the 
cytoplasm and nucleus of the blast 
cells. The percentage of positive 
cells was scored semi-quantitatively. 
Regarding the cytoplasmic staining, the 
scoring method was as follows: 0 = no 
expression, 1 = cytoplasmic staining 
in less than 10% of the blast cells, 2 
= cytoplasmic staining in 10-25% of 
the blast cells, 3 = cytoplasmic staining 
in 26-50% of the blast cells and 4= 
cytoplasmic staining in more than 50% 
of the blast cells. The representative 
images for each scoring are shown in 
Figure 2. The percentage of positive 
blasts for the nuclear staining was 
much less than the cytoplasmic thus 
the scoring method was as follows: 0 
= no expression, 1 = ≤10% of the blast 
cells and 2 = >10% of the blasts.
STAINING INTENSITY
The definition of staining intensity 
was based on report published by 
Byers et al. (2011).  The staining 
intensity, for both cytoplasmic and 
nuclear which indicates the density of 
staining, was scored as follows: 0 = no 
expression, 1+ = weak expression, 2+ 
= moderate expression and 3+ = strong 
expressions. The representative images 
for each intensity for both cytoplasmic 
and nuclear are shown in Figure 3 and 
4, respectively.
 The expression of Msi2 for percentage 
positive staining and staining intensity 
was divided into two subgroups i.e. 
low Msi2 expression and high Msi2 
expression. The AML cases where the 
cytoplasmic staining scoring for Msi2 
Figure 1: Positive control. Placental tissue 
showing strong positive Msi2 staining in 
trophoblast (x60)
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Figure 2: Percentage of positive blast cells. Bone marrow trephine biopsy sections showing the 
cytoplasmic staining and the scoring values in different cases of AML positive for Msi2 (A) score 0, 
(B) score 1, (C) score 2, (D) score 3 and (E) score 4. (x4)
Figure 3: Cytoplasmic staining intensity. Bone marrow trephine biopsy sections showing different 
cytoplasmic staining intensities in different cases of AML positive for Msi2 (A) 1+, (B) 2+, and (C) 3+. 
(x60)
Figure 4: Nuclear staining intensity. Bone marrow trephine biopsy sections showing different nuclear 
staining intensities in different cases of AML positive for Msi2 (A) 1+, (B) 2+, and (C) 3+. (x60)
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was scored as 1 and 2 were considered 
as low Msi2 expression. Whereas, the 
AML cases with cytoplasmic staining 
scoring of 3 and 4 were considered 
as high Msi2 expression. For the 
cytoplasmic staining intensity, the weak 
expression (1+) was regarded as low 
Msi2 expression, whereas, the AML 
cases with moderate (2+) and strong 
(3+) Msi2 expression were considered 
as high Msi2 expression.
CYTOGENETICS
Cytogenetic analysis using G-banding 
technique was performed on 
metaphases from bone marrow 
aspirates taken at diagnosis with the 
use of standard procedures and all 
cases were performed at UKMMC 
cytogenetics laboratory.
STATISTICAL ANALYSIS 
Data collected was entered into a 
computer file and statistically analysed 
using IBM Statistical Package for Social 
Sciences (SPSS) version 21.0 statistic 
software. Descriptive analysis of the 
data was performed in numbers and 
percentages for Msi2 staining as well 
as for demographic variables. Chi-
square test was conducted to analyse 
the relationship of Msi2 expression 
to AML, and also to correlate Msi2 
expression with clinicopathological 
parameters and OS. Finally, Kaplan-
Meier survival analysis was performed 
to measure the outcome with Msi2 
expression. A P value of <0.05 was 
considered significant.
RESULTS
DEMOGRAPHIC DATA OF 
PATIENTS AND CLINICAL 
PARAMETERS 
A total of 64 patients were included 
in this study. All patients included 
received intensive chemotherapy 
according to standard AML protocols. 
Patients’ age ranged from 1-81 yrs 
with two peaks incidence, the first 
peak between 10-15 yrs of age and the 
second peak between 35-45 yrs of age 
(median = 30 yrs). Follow-up data for 
52 patients were available. Out of the 
52 patients 38(59.4%) succumbed to 
their malignancy early on the course of 
follow-up before reaching 5 yrs and 14 
patients (21.9%) were still alive at the 
end of the follow-up period. Patient 
demographics are summarized in 
Table 1.
EXPRESSION OF MSI2 IN AML 
ON BONE MARROW TREPHINE 
SECTIONS 
The positive cases for Msi2 were 61 
cases (95.3%), whereas, 3 cases (4.7%) 
were negative. Total cellular positivity 
(cytoplasmic and nuclear staining) 
was demonstrated in 46 cases (71.9%) 
and 15 cases (23.4%) showed only 
cytoplasmic positivity. There were 
no cases that showed only nuclear 
staining.
CYTOPLASMIC STAINING SCORING
Out of 64 cases of AML, 11 cases 
(17.2%) showed score 1, 15 cases 
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(23.4%) showed score 2, 15 cases 
(23.4%) showed score 3 and 20 cases 
(31.3%) showed score 4. Total absence 
of Msi2-positive cells (score 0) was 
observed in 3 cases (4.7%).
CYTOPLASMIC STAINING INTENSITY 
SCORING
In 64 cases of AML, Msi2 showed 
variability in staining pattern 
Table 1: Shows demographics of the patients with AML
Parameters
Patients
Total
NO %
Age 62
<60 years                                                  48 75.0
  ≥60 years                                                  14 21.9
Not available                                              2 3.3
WBC count at diagnosis 64
  ≤10×10⁹/L                                                 20 31.3
>10× 10⁹/L      44 68.6
FAB classification 52
  M0 0 0.0
  M1 0 0.0
  M2 2 3.1
  M3 10 15.6
  M4 19 29.7
  M5 13 20.3
  M6 6 9.3
  M7 2 3.1
Not available                                            12 18.8
Cytogenetic category 49
  Favorable                                                  14 21.9
  Intermediate                                              28 43.8
Adverse     7 10.9
Not available                                            15 23.4
Remission status post induction 39
  Achieve remission                                    19 29.7
  Did not achieve remission                  20 31.3
Not available                                            25 39.1
Overall survival 52
≤5 years                                                    38 59.4
>5 years                                                    14 21.9
Not available                                            12 18.8
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(representative images at each intensity 
for cytoplasmic intensities is shown in 
Figure 5). There were 19 cases (29.7%) 
showed weak expression (1+), 30 cases 
(46.9%) showed moderate expression 
(2+), 12 cases (18.8%) showed strong 
positivity (3+) and 3 cases (4.7%) 
showed negative staining for Msi2.
NUCLEAR STAINING SCORING 
The majority of the cases (39.1%) 
showed score 2 for nuclear staining 
and 21 cases (32.8%) showed score 
1, whereas, 18 cases (28.1%) were 
negative for nuclear staining.
NUCLEAR STAINING INTENSITY 
SCORING
Out of 64 cases of AML, 18 cases 
(28.1%) showed no nuclear staining and 
only three cases (4.7%) showed strong 
positivity (3+). There were 27 cases 
that (42.2%) showed weak expression 
(1+) and 16 cases (25%) that showed 
moderate expression (2+). 
CORRELATION OF MSI2 
EXPRESSION WITH CLINICAL 
PARAMETERS
Correlation of Msi2 expression with 
the clinical parameters and OS for 
the cytoplasmic staining and total 
cellular staining were performed, 
whereas, nuclear staining was not 
performed as there were no cases 
showed only nuclear staining. Finally, 
Msi2 expression of the total cellular 
positivity was correlated with the 
clinical parameters and OS.
Figure 5: Cytoplasmic staining intensity scoring. Representative bone marrow trephine biopsy 
sections showing cytoplasmic staining intensities for Msi2 in different cases of AML (A) score 0, (B) 
score 1+, (C) score 2+ and (D) score 3+. (x4, x60, x40, x40, respectively).
A B
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CORRELATION OF THE 
CYTOPLASMIC STAINING 
SCORING AND CYTOPLASMIC 
STAINING INTENSITY OF MSI2 
EXPRESSION WITH CLINICAL 
PARAMETERS 
Regarding the correlation between the 
cytoplasmic staining scoring of Msi2 
expression and the patients' age, low 
expression of Msi2 was observed in 
25 (14.0%) cases and 36 (59.0%) cases 
showed high Msi2 expression. There 
was no significant correlation between 
the two age groups at any level of 
staining (P = 0.4). For WBC count, there 
was no significant correlation between 
the low and high Msi2 expression for the 
cytoplasmic staining scoring in the two 
groups (P = 0.3). Similarly, there were 
no significant correlations between the 
two subgroups of Msi2 expression and 
the eight FAB subtypes (P = 0.3), the 
three cytogenetic subtypes (P = 0.2), 
the two groups of the remission status 
post induction chemotherapy (P = 0.7) 
and the two groups of OS (P = 0.8). The 
correlation between the cytoplasmic 
staining scoring of Msi2 expression 
with clinical parameters is summarized 
in Table 2. For the correlation between 
the cytoplasmic staining intensity 
of Msi2 expression and the clinical 
parameters, our results showed there 
were no significant correlations at 
any level of staining.  The results are 
summarized in Table 3. 
CORRELATION OF THE TOTAL 
CELLULAR STAINING OF MSI2 
EXPRESSION WITH CLINICAL 
PARAMETERS 
The information regarding patients’ age 
was available in 61 cases. Out of 61 
cases 46 (75.4%) cases showed total 
cellular staining and 15 cases (24.6%) 
showed only cytoplasmic staining 
of Msi2. There was no significant 
correlation between the two groups (P = 
0.9). Similarly, there were no significant 
correlations between both total cellular 
or cytoplasmic staining with WBC 
count or FAB subtypes (P = 0.7 and P 
= 0.1, respectively). Interestingly, our 
results showed significant correlation 
between the intermediate cytogenetic 
category and the Msi2 expression in 
the total cellular staining (P = 0.04). 
Neither total cellular nor cytoplasmic 
staining were significantly correlated 
with the remission status post induction 
chemotherapy or OS (P = 0.8 and P 
= 0.5, respectively). The correlation 
of the total cellular staining of Msi2 
expression with the clinical parameters 
is summarized in Table 4.
KAPLAN-MEIER SURVIVAL 
ANALYSIS 
Neither cytoplasmic staining scoring, 
nor cytoplasmic staining intensity of 
Msi2, nor total cellular staining were 
significantly associated with outcome 
by Kaplan-Meier analysis for values 
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low or high expression of Msi2 (P = 
0.7, P = 0.5, and P = 0.4, respectively). 
Because our results showed significant 
correlation between the cytogenetic 
categories and the expression of Msi2 
in cases with total cellular positivity, 
further; Kaplan-Meier survival analysis 
was performed within the cytogenetic 
subgroups. There was no significant 
correlation between the three groups 
(P = 0.1). 
DISCUSSION 
Acute myeloid leukaemias (AMLs) are 
aggressive haematological neoplasms 
that require urgent treatment (Munker 
2007). Despite intensive treatment 
with chemotherapy, only a minority 
of patients can be cured at present 
(Munker 2007). Hope et al. (2010) 
mentioned that, for the development 
of novel targeted therapies aimed 
Table 2: Shows correlation of the cytoplasmic staining scoring of Msi2 expression with 
the clinical parameters
Patients demographics 
(Number of patients) Msi2 low (%)      Msi2 high (%)        P Value
Age 0.4
<60 years   (47)          18 (38.3) 29 (61.7)
  ≥60 years   (14)                                            7 (50.0) 7 (50.0)
WBC count at diagnosis 0.3
  ≤10×10⁹/L  (20)                                           10 (50.0) 10 (50.0)
>10× 10⁹/L (41)                                           15 (36.6) 26 (36.4)
FAB classification 0.3
M0 (0)                                                              0 (0.0) 0 (0.0)
  M1 (0)                                                              0 (0.0) 0 (0.0)
  M2 (2)                                                            1 (50.0) 1 (50.0)
M3 (10)                                                          3 (30.0) 7 (70.0)
M4 (19)                                                        6 (31.6) 13 (68.4)
  M5 (11)                                                          7 (63.6) 4 (36.4)
  M6 (6)                                                          2(33.3) 4 (66.7)
M7 (1)                                                              1 (100.0) 0 (0.0)
Cytogenetic category 0.2
Favorable (14)                                                7 (50.0) 7 (50.0)
  Intermediate (27)                                         7 (25.9) 20 (74.1)
Adverse (7)                                                    3 (42.9) 4 (57.1)
Remission status post induction 0.7
Achieve remission (18) 7 (38.9) 11 (61.1)
Did not achieve remission (20) 9 (45.0) 11 (55.0)
Overall survival 0.8
≤5 years (37)                                                16 (43.2) 21 (56.8)
>5 years (13)                                                  6 (46.2) 7 (53.8)
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at reigning in leukaemic stem cells, 
the understanding of the molecular 
machinery that controls HSC self-
renewal is critical. Msi2 protein is 
a protein recently identified as a 
regulator of the HSCs compartment 
and of leukaemic stem cells (Kharas 
et al. 2010), and a poor prognostic 
biomarker of survival, both in mRNA 
and protein expression studies (Back 
et al. 2013). This knowledge has led its 
use as a novel prognostic marker and 
proposed as a new target for therapy 
in AML (Back et al. 2013; Park et al. 
2015). This is particularly important in 
CN-AML, where CN-AML is the largest 
cytogenetic subgroup of the disease 
and is marked by heterogeneous 
survival (Foran 2010). 
 The present study showed that the 
incidence of AML is high in young 
population, i.e. 60 yrs and younger. 
Table 3: Shows correlation of the cytoplasmic staining intensity of Msi2 expression with 
the clinical parameters
Patients demographics
(Number of patients) Msi2 low (%)      Msi2 high (%)        P Value
Age 0.9
<60 years   (47)          14(29.8) 33 (70.2)
  ≥60 years   (14)                                            5 (35.7) 9 (64.3)
WBC count at diagnosis 0.6
  ≤10×10⁹/L  (20)                                           7 (35.0) 13 (65.0)
>10× 10⁹/L (41)                                           12 (29.3) 29 (70.0)
FAB classification 0.2
M0 (0)                                                              0 (0.0) 0 (0.0)
  M1 (0)                                                              0 (0.0) 0 (0.0)
  M2 (2)                                                            1 (50.0) 1 (50.0)
M3 (10)                                                          3 (30.0) 7 (70.0)
M4 (19)                                                        5 (26.3) 14 (37.7)
  M5 (11)                                                          5 (45.5) 6 (54.5)
  M6 (6)                                                          0 (0.0) 6 (100.0)
M7 (1)                                                              1 (100.0) 0 (0.0)
Cytogenetic category 0.1
Favorable (14)                                                6 (42.9) 8 (57.1)
  Intermediate (27)                                         5 (18.5) 22 (81.5)
Adverse (7)                                                    3 (42.9) 4 (57.1)
Remission status post induction 0.1
Achieve remission (18) 8 (44.4) 10 (55.6)
Did not achieve remission (20) 4 (20.0) 16 (80.0)
Overall survival 0.7
≤5 years (37)                                                13 (35.1) 24 (64.9)
>5 years (13)                                                  6 (46.2) 7 (53.8)
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The median age of all cases was 30 yrs. 
Though the literature shows that the 
incidence of AML is higher in elderly 
(>60 yrs age), and the median age at 
presentation usually between 60 and 
70 yrs.
 It should be recalled that the majority 
of patients (68.8%) had WBC count 
more than 10x10⁹/L at diagnosis in 
keeping with the literature review. The 
FAB subtypes of patients in our study 
showed that the majority of patients 
belong to M4 (29.7%) followed by M5 
(20.3%). None of the patients in this 
study belong to M0 or M1 subtype. 
Kumar (2011) reported higher incidence 
of M2 (25%) followed by M4 (20%). 
Similarly, Byers et al. (2011) showed a 
higher percentage of patients with M2.
The diagnostic karyotype provides 
the framework for risk-stratification 
schemes in AML (Grimwade et al. 
Table 4: Shows correlation of the total cellular staining of Msi2 expression with the 
clinical parameters
Patients demographics 
(Number of patients)
Total cellular staining 
(%)      
Cytoplasmic staining 
(%)               P Value
Age 0.9
<60 years   (47)          36 (67.6) 11 (23.4)
  ≥60 years   (14)                                            10 (71.4) 4 (24.6)
WBC count at diagnosis 0.7
  ≤10×10⁹/L  (20)                                           14 (70.0) 6 (30.0)
>10× 10⁹/L (41)                                           32 (78.0) 9 (22.0)
FAB classification 0.1
M0 (0)                                                              0 (0.0) 0 (0.0)
  M1 (0)                                                              0 (0.0) 0 (0.0)
  M2 (2)                                                            1 (50.0) 1 (50.0)
M3 (10)                                                          6 (60.0) 4 (40.0)
M4 (19)                                                        16 (84.2) 3 (15.8)
  M5 (11)                                                          7 (63.6) 4 (36.4)
  M6 (6)                                                          6 (100.0) 0 (0.0)
M7 (1)                                                              0 (0.0) 1 (100.0)
Cytogenetic category 0.04
Favorable (14)                                                8 (57.1) 6 (42.9)
Intermediate (27)                                         24 (88.9) 3 (11.1)
Adverse (7)                                                    4 (57.1) 3 (42.9)
Remission status post induction 0.8
Achieve remission (18) 13 (72.2) 9 (24.3)
Did not achieve remission (20) 16 (80.0) 4 (20.0)
Overall survival 0.5
≤5 years (37)                                                28 (75.7) 9 (24.3)
>5 years (13)                                                  8 (61.5) 5 (38.5)
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2010). The majority of patients in this 
study showed normal cytogenetic 
finding with normal karyotype. The 
cytogenetic findings in this study 
showed that the majority of patients 
(43.8%) belong to the intermediate 
cytogenetic subgroup. These data 
were comparable to that previously 
reported in the literature. Moreover, 
there were only 39 BM aspirates 
from patients with AML available for 
assessment of the remission status 
post induction as 25 of them had 
succumbed to their illness early on the 
course of follow-up before detecting 
their remission status. Meanwhile, the 
analysis from these groups showed that 
the data were comparable between the 
group of patients who had achieved 
remission versus the group that did not 
achieve remission (29.7% vs 31.3%, 
respectively).
 In the present study, we identified 
the OS of patients with AML related to 
the MSi2 expression. Follow-up data on 
OS was performed in only 52 patients 
as 12 patients defaulted treatment. 
The majority of our cases (59.4%) 
succumbed to their malignancy early 
on the course of follow-up (<5years). 
The most common cause of death was 
neutropenic sepsis (48.4% of cases). 
Hämäläinen et al. (2009) mentioned 
that severe sepsis is an important cause 
of treatment-related morbidity and 
mortality in AML and demonstrated 
in his study that severe sepsis was 
found in 13% of AML patients. He also 
found that severe sepsis was associated 
with 27% mortality in AML patients 
(Hämäläinen et al. 2009). The reason 
being that during chemotherapy, 
patients with AML have a great risk of 
life-threatening infections because of 
neutropenia due to the chemotherapy 
and the disease as well, combined 
with damage to the mucosal barrier 
and impairment of the innate immune 
system induced by chemotherapy 
(Hoffbrand et al. 2011). 
The identification of Msi2 as poor 
prognosticator by its strong association 
with outcome in cases with AML 
was demonstrated by Kharas et al. 
(2010) and Byers et al. (2011). Their 
findings prompted us to investigate 
the expression of Msi2 in our own 
population of AML. Byers et al. (2011) 
reported immunohistochemically 
demonstrable Msi2 expression in both 
the cytoplasm and nucleus of 70% of 
the blast cells in all AML examined.
 It should be mentioned that this 
work studied 64 cases of AML for 
expression of Msi2. Positivity for 
Msi2 were demonstrated in 61 cases 
(95.3%), whereas, 3 cases (4.7%) 
were negative. In 46/64 (71.9%) cases 
the blast cells showed total cellular 
positivity (cytoplasmic and nuclear 
staining), 15/64 (42.2%) cases showed 
only cytoplasmic staining. There were 
no cases showed only nuclear staining. 
However, Byers et al. (2011) reported 
that some of their cases showed 
nuclear staining only. 
 The present study observed that the 
blast cells in some of the cases showed 
interstitial pattern of staining, whereas, 
in others; the blast cells showed positive 
staining in sheets. Haematopoietic 
cells such as myeloid, erythroid 
and megakaryocytes were negative. 
Additionally, the cytoplasmic staining 
was more frequent than the nuclear 
staining for all levels of staining. These 
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findings were consistent with previous 
report by Byers et al. (2011). 
 The results of the present study 
showed that the majority of the cases 
had high expression of Msi2 for 
cytoplasmic staining. In contrast to 
Byers et al. (2011) revealed a lower 
percentage of positivity in most of the 
cases. The present study did not find 
significant correlations between Msi2 
expression, neither the cytoplasmic 
(staining scoring nor staining intensity) 
nor the total cellular staining, and the 
clinical variables recorded (age, WBC 
count at diagnosis, FAB subtypes, 
remission status).
 The results of the present study 
showed that the only clinical parameter 
correlated with Msi2 expression 
was the cytogenetics. The study 
demonstrated significant correlation 
between the total cellular staining 
and the intermediate cytogenetic 
subgroup (P = 0.04). In contrast to 
Byers et al. (2011) which did not show 
significant correlation between Msi2 
and cytogenetics, however; their study 
demonstrated significant correlation 
between total cellular staining as well as 
the nuclear staining and FAB subtypes. 
No significant correlation was found 
between Msi2 expression with OS in 
the present study. This result could be 
due to limited data available (OS for 52 
patients only).
 Finally, the Kaplan-Meier overall 
survival analysis, showed that neither 
cytoplasmic (staining scoring nor 
staining intensity) nor total cellular 
staining were significantly associated 
with overall survival. Furthermore, 
we performed Kaplan-Meier survival 
analysis within the cytogenetic 
subgroups, but our results, also 
showed that there was no significant 
correlation with the outcome. These 
results were in contrast to Byers et al. 
(2011) study which demonstrated that 
strong staining (3+) of Msi2 expression 
was associated with poor outcome 
for both total cellular and nuclear 
positivity using Kaplan-Meier survival 
analysis. Additionally, their study 
showed significant correlation between 
the favorable cytogenetic subgroup 
and the outcome (Byers et al. 2011). 
Another study by Back et al. (2013), 
using Kaplan-Meier survival analysis, 
recognized that elevated levels of both 
HOXA9 and Msi2 were associated 
with a shorter survival time and, on the 
other hand, single protein expression 
for either HOXA9 or Msi2 was not 
significantly associated with survival. 
 We humbly admit few limitations of 
the study. Our sample size was small. 
We did not compare the results using 
any other image analysis system. Due 
to constraint in the budget, we did 
not perform any additional marker 
needed for mutational study which 
is usually employed by World Health 
Organization (WHO) to classify AML. 
We admit that there was no correlation 
seen between the intermediate 
cytogenetic subgroup of AML and the 
OS, but we think that with a larger 
sample size and using additional 
molecular analysis could result in 
significant findings.
CONCLUSION
The present study found that Msi2 
protein expression was demonstrated 
in the majority of our AML patients 
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whereby it is beneficial in daily 
practice for newly diagnosed AML 
patients. Furthermore, the majority of 
the cases had high expression of Msi2 
and showed variability in staining 
pattern. This variability in the staining 
pattern prompt pathologists to be 
aware of that during interpretation 
of immunostaining result.  The study 
also showed that the total cellular 
staining of Msi2 correlated with the 
intermediate cytogenetic subgroup. 
However, our study did not find any 
correlation between Msi2 expression 
and OS and other clinicopathologic 
variables recorded. These debatable 
results provide new area for researchers 
to conduct further researches to 
determine the role of Msi2 positive 
blast cells in AML and their association 
with prognosis and outcome.
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